beating advanced cancer - resi longevity

Beating advanced cancer

2 | INTENDED FOR PRIVATE AUDIENCE: PLEASE DO NOT DISTRIBUTE WITHOUT PERMISSION

xCures Brief

Beating cancer by enabling patients and their doctors to prioritize and access the best treatments and tests

Patented AI and ML tools integrate public data, proprietary knowledge and expert insights

Creating a learning system that efficiently incorporates results from all patients, on all therapies, all the time

xCures AI

Public Data• Clinicaltrials.gov• NCCN Guidelines

Proprietary Outcomes Data• RWE• PRO

Literature

Virtual Tumor Boards

• Incorporated April 2018• 25 team members with virtual and physical offices in Bay Area, CA and Research Triangle, NC• $5M Series Seed, Post-Money $11M, Jan 2020• Revenue $1M in 2020; Forecasting $4.5M in 2021 and $10M+ in 2022; milestone and royalties +$15M• Raising $8-10M Series A


xCures a Patient-Centric Precision Oncology Platform

xCures empowers advanced cancer patients by identifying the best treatment options for them to consider with their physician, tracking their outcomesand continuously learning from every interaction.

xCures serves as a platform for partners: enabling access to products and services; and gathering Real World Evidence (RWE) to accelerate development and commercialization.


Based on Navigation and Advocacy for 10,000+ Patients1980 2010 20212015

• Medical School• Publications• Medical Texts

• Public databases• Search Engines

• Access to experts• Services platform

• Real world evidence (RWE)• Augmented intelligence• Predictive models


Advanced Cancer Patients

• Exhausted standard of care• Cannot tolerate, or who are not responding to standard of care• Less than a 50% chance of 5-year survival


● Scared ● Confused● Urgent need to find innovative therapies● Want help in understanding options● Must identify how to access the options

Advanced Cancer Patients Need Help

*Based on interviews with Cancer Common Patients in Q4’2020


Oncologists are Overwhelmed

● 12,940 Oncologists1

○ By 2025, there would be a shortage of ~2,250 oncologists2

● 1.7MM new diagnoses per year

● 134 specialists per 10,000 in urban vs. 40 per 10,000 in rural areas3

● NCI lists 607 approved or standard treatment options4

○ Even more treatment options in development

● NCCN has 72 treatment guidelines by cancer type5

○ Each guideline is 100-300 pages

○ Complexity of guidelines is increasing6

○ Many cancers have 30+ recognized sub-types with different accepted treatments

● There are 432 genes and more than 2,300 actionable variants implicated in cancer7

○ 457 different drugs targeting those genes/variants 1. https://www.asco.org/research-guidelines/reports-studies/state-cancer-care. 2. https://ascopubs.org/doi/full/10.1200/JOP.2013.0013193. https://www.cancernetwork.com/view/challenges-rural-cancer-care-united-states4. https://www.cancer.gov/about-cancer/treatment/drugs5. https://www.nccn.org/professionals/physician_gls/default.aspx#site

6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070231/7. https://civicdb.org/home

https://www.asco.org/research-guidelines/reports-studies/state-cancer-care

https://ascopubs.org/doi/full/10.1200/JOP.2013.001319

https://www.cancernetwork.com/view/challenges-rural-cancer-care-united-states

https://www.cancer.gov/about-cancer/treatment/drugs

https://www.nccn.org/professionals/physician_gls/default.aspx

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070231/

https://civicdb.org/home


Opportunity: Generate Insights Outside of Clinical Trialsclinical trial

2-4 years

Excluded from clinical trials

• Advanced cancer kills over 600,000 annually in the US

• >95% of patients cannot participate in clinical trials

Therapy 1

“Fewer than 1 in 20 adult cancer patients enroll in cancer clinical trials. But although barriers to trial participation have been the subject of frequent study, the rate of trial participation has not changed substantially over time. Barriers to trial participation are structural, clinical, and attitudinal, and differ according to demographic and socioeconomic factors. . .”

Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. 2016;35:185-98. doi: 10.1200/EDBK_156686. PMID: 27249699; PMCID: PMC5495113.




Prospective Observational Studies Using RWEclinical trial

2-4 years

Therapy 1

Therapy 2

Therapy 3

Therapy 4

Therapy 5

Therapy 6

Therapy 7

Therapy 8

RWE + Adaptive Bayesian Trial Designs

Learning from all the patients!


Know the Treatments• What should be considered• How to get it

Recommend and Learn• Understand Oncology• Capture Knowledge

RWE Generation• Master Protocol for GCP• HIPAA compliant storage• Data structured in EDC

Options Library• Treatment options• Medical rationales• Access mechanisms

AI and ML• NLP• Predictive model• Expert Insights

Three Critical Challenges Solved

Know the Patient• Current Clinical Situation• Longitudinal Outcomes

Challenge

Solution


Mika NewtonCEO

• 20+ years of leadership experience in healthcare. Former Chief Commercial Officer of Doctor Evidence, LLC., GM of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes.

• Management and operations roles at Quintiles, Invitrogen and Tripos.

Kenny Wong, MSCPO

• 10+ years in product management in healthcare. Board certified genetic counselor with 40+ publications/abstracts/medical conference presentations.

• Former VP of Products with GenomeSmart (sold to Ambry Genetics in 2020) and Senior Product Director at Counsyl (sold to Myriad Genetics in 2018).

Mark Shapiro, MBA, MAVP, Clinical Development

• Pharmacologist and widely recognized expert in innovation strategies in clinical research and development.

• Former SVP, Operations at Clinipace, a global oncology-focused CRO, part of team that grew organization from 10 to over 1000 employees worldwide.

Jeff Shrager, PhDDirector of Research

• 20+ years experience in applying high performance cloud computing and machine learning in biological science.

• Formerly with Xerox PARC and SRI International's biological AI-group and co-founder of several successful computational drug discovery and genomics companies.

Marty Tenenbaum, PhDChairman

• Renowned computer scientist, internet commerce entrepreneur and cancer survivor. Founder of Cancer Commons.

• Founder of CollabRx (NASD: CRLX), EIT (sold to Verifone in 1995) and CommerceNet (1994). Former officer at Commerce One, Webify (sold to IBM in 2006), Medstory (sold to Microsoft in 2007), Patients Like Me, and Public Library of Science (PLoS).

Glenn Kramer, PhDCTO

• Product development expert in AI-based constraint systems, business intelligence, and computational finance. Head, Internet Consulting, EIT (sold to VeriFone, 1995). Director, Software Architecture, VeriFone (sold to HP, 1998). Holds 22 issued US Patents.

• Most recently Chief Data Scientist at SRS Acquiom (acquired by Lovell Minnick, 2018), where he developed innovative SEC-registered financial products using predictive analytics.

William Hoos, MS, MBACCO

• Life science executive and investor with extensive experience with drug and diagnostic companies in oncology.

• Former CEO of NQ Oncology, consultant to OncoPlexDiagnostics, nonprofit experience with Pancreatic Cancer Action Network and as founder of ClinWiki.

Santosh Kesari, MD, PhDCMO, Consulting

• Chair and Professor, Department of Translational Neuro-oncology and Neurotherapeutics, John Wayne Cancer Institute

• Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance

The Right Team


Scientific Advisory Board

– KEITH T. FLAHERTY, MD. Massachusetts General Hospital (Chair)

• Professor, Medicine, Harvard Medical School

• Director of Henri and Belinda Termeer Center for Targeted Therapy, Cancer Center, Massachusetts General Hospital

• Director of Clinical Research, Cancer Center, Massachusetts General Hospital

– PATRICIA LORUSSO, DO. Yale Cancer Center

• Professor of Medicine (Medical Oncology)

• Professor of Medicine

• Associate Director of Experimental Therapeutics

– JENNIFER GRANDIS, MD. University of California San Francisco

• American Cancer Society Professor, Otolaryngology

• Professor of Otolaryngology – Head and Neck Surgery (OHNS)

• Associate Vice Chancellor – Clinical and Translational Research (AVC-CTR)

– JOSH TENENBAUM, PHD - Professor of Cognitive Science and Computation, Massachusetts Institute of Technology; MacArthur Fellow

– CRAIG LIPSET - Former Head of Clinical Innovation at Pfizer

– ELIZABETH HUTT POLLARD - Executive Chair Applied Silver; Former CEO NuGEN Technologies; Secretary of Science and Innovation, OK; YBO Global Board Director

– DAVID HARTFORD - Senior Advisor and Board Member multiple PE and VC organizations

– ROBERT RODIN - Chairman and CEO RDN Group; Former CEO Marshall Industries

– LAURENCE MARTON, MD - Member BOD xCures; Former Dean of Medicine at University of Wisconsin; Former Chair Department of Laboratory Medicine UCSF

Advisory Board


Patient Centric Platform

Managed Access CRO

Provider Focused CDS

Retrospective RWE

Competitive Landscape

Value t

o Pati

ents


Funding Strategy

$8-10M Series A 2021

We’re seeking the right partners to help us scale

• Scale business development

• Expand into a high-volume cancer (i.e. breast, lung, colon)

• Scale operations, engineering, AI and data science for exponential growth

• Refine and execute regulatory strategy for SaMD

Appendix

beating advanced cancer - resi longevity

Documents